Clarivate Plc (CLVT) Q4 2025 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

The company demonstrated strong financial performance with positive ACV growth, stable revenue retention, and improved EBITDA and cash flow. The Q&A highlighted optimism in AI product monetization and strategic synergies. Despite some unclear responses, the raised revenue guidance and focus on debt repayment over buybacks are seen as value-creating moves, suggesting a positive stock price movement.

Key Financial Performance

Organic ACV Growth Nearly 2% organic ACV growth, representing approximately 90 basis point improvement year-over-year. This was achieved through improved sales execution and innovation.

Organic Recurring Revenue Mix Improved to 88%, showing progress towards a more predictable subscription-based model.

Adjusted EBITDA Delivered more than $1 billion, reflecting strong operational performance.

Free Cash Flow $365 million, a 2% growth over the prior year, driven by lower working capital, capital spending, interest, and taxes.

Revenue Retention Rates Stable at 93%, indicating strong customer retention.

Academia & Government Organic ACV Growth Achieved 2% growth despite funding headwinds in the U.S. academic market.

Intellectual Property Annuities Revenue Improved by 270 basis points year-over-year due to stronger execution.

Q4 Revenue $617 million, with the full year revenue at $2.455 billion. Changes were inorganic due to disposals and divestitures.

Q4 Net Income $3 million, a $195 million improvement over Q4 of the prior year, driven by noncash impairment charges not recurring and lower income tax and interest expense.

Operating Cash Flow $160 million in Q4, a $19 million improvement compared to last year, driven by working capital and lower interest and taxes.

You have reached the limit. Sign up to access full content

Get started

Operating Highlights

AI-powered features and products: Introduced 12 major products and AI-powered features in 2025, including AI research assistants, workflow agents, and ecosystem access tools like Nexus.

AI integration: AI is being used to enhance proprietary data and customer workflows, with tools like conversational search and digital analysts for tasks like patent monitoring.

Market focus shift: Initiated the process to sell the Life Sciences & Health business to focus on Academia & Government (A&G) and Intellectual Property (IP) markets.

Global reach: Serving over 45,000 customers globally with proprietary solutions.

Revenue retention: Achieved stable revenue retention rates of 93% and improved recurring revenue mix to 88%.

Financial performance: Delivered $1 billion in adjusted EBITDA and $365 million in free cash flow in 2025, with a 10% free cash flow growth target for 2026.

Portfolio simplification: Strategic review led to the decision to sell the Life Sciences & Health segment to reduce leverage and focus on core markets.

AI strategy: Leveraging AI to amplify proprietary data and enhance customer workflows, turning AI adoption into a growth opportunity.

You have reached the limit. Sign up to access full content

Get started

Risk or Challenges

AI Disruption Concerns: The market has expressed concerns about potential AI disruption for software and information services companies. While the company believes its proprietary assets and AI strategy mitigate this risk, it remains a potential challenge.

Life Sciences & Health Business Sale: The company is in the process of selling its Life Sciences & Health business. There is no guarantee of reaching an agreement, and failure to do so could impact strategic objectives and financial performance.

Funding Headwinds in U.S. Academic Market: The Academia & Government segment faced funding headwinds in the U.S. academic market, which could impact future growth in this segment.

Transactional Revenue Decline: The company has transitioned away from transactional revenues, which has led to a decline in organic revenue. This could pose challenges in maintaining overall revenue growth.

Patent Renewal Accelerations: The company experienced mid-single-digit organic growth in recurring revenues in Q1 2025 due to patent renewal accelerations in the U.S., which are not expected to recur in 2026, potentially impacting revenue.

Economic Uncertainty: Economic uncertainties, including foreign exchange fluctuations and inflation, could impact financial performance and operational costs.

Strategic Execution Risks: The company’s ability to execute its value creation plan, including cost efficiencies, innovation, and portfolio simplification, is critical. Any missteps could adversely affect financial and operational performance.

You have reached the limit. Sign up to access full content

Get started

Guidance & Outlook

Free Cash Flow Growth: Guidance for 2026 includes a 10% growth in free cash flow, reaching approximately $400 million.

Revenue Retention Rates: Stable revenue retention rates of 93% are expected to continue.

Proprietary Revenue Contribution: 97% of revenue is expected to come from proprietary solutions, enhanced by AI.

Life Sciences & Health Business Sale: The company is in active discussions to sell its Life Sciences & Health business, which could accelerate value creation and strengthen the balance sheet through reduced leverage.

AI Strategy and Product Development: AI is being leveraged to enhance proprietary data and deliver solutions such as AI research assistants, workflow agents, and ecosystem access. Over 10 additional AI solutions are planned for release in 2026.

Academia & Government Segment: Organic growth acceleration is expected, supported by AI innovation and improving market dynamics.

Intellectual Property Segment: Positive outlook with additional AI product launches planned for 2026 and a return to growth anticipated.

Life Sciences & Health Segment: Expected return to organic revenue growth in 2026, supported by consistent quarterly ACV growth and pipeline visibility.

Organic Annual Contract Value Growth: Guidance for 2026 includes 2% to 3% organic ACV growth, a meaningful acceleration from prior years.

Recurring Organic Revenue Growth: Targeting 1% to 2% growth in 2026, an improvement of almost 100 basis points compared to last year.

Adjusted EBITDA Margin: Expected to expand by about 200 basis points in 2026, driven by organic growth, cost management, and strategic disposals.

Capital Allocation: Plans to focus on deleveraging and potential proceeds from the sale of the Life Sciences & Health business.

You have reached the limit. Sign up to access full content

Get started

Shareholder Return Plan

Share Buyback Program: We used the free cash flow we generated to buy back $225 million worth of stock, and we called $100 million of the bonds that were due later this year and then called the remaining $100 million in January of 2026. This balanced deployment of capital allowed us to maintain net leverage at approximately 4 turns while retiring $56 million or 7% of our outstanding shares.

You have reached the limit. Sign up to access full content

Get started

Key Q&A

Q:Can you talk about your monetization model for subscriptions and new AI products?

A:The company continues to use AI to protect and grow subscription revenue, with upsell opportunities for AI innovations and new products. Pricing models vary by product, with some based on the size of the institution and others on the actual end users. Renewal rates and usage are increasing, and the company is optimistic about its progress.

Q:Can you explain the 97% of revenue coming from proprietary data and how tech-enabled workflows fit into that?

A:97% of the business is derived from proprietary data, with 60% from information services and 20% from enterprise software. Proprietary data is created, enhanced, and embedded into customer workflows, providing unique value. Examples include Web of Science for academia and Cortellis for pharmaceutical companies. The company emphasizes the importance of transparency, auditability, and governance in its offerings.

Q:What were the key considerations for initiating a sale process for the Life Sciences & Healthcare business?

A:The decision aligns with the company's value creation plan to focus on shareholder value. The Life Sciences segment was identified as an opportunity for sale to increase focus on Academia & Government (A&G) and Intellectual Property (IP) segments. The company benefits from shared content, technology platforms, and commercial channels between A&G and IP.

Q:Can you elaborate on the strategic synergies between IP and Academia & Government?

A:The company benefits from shared content, technology platforms, and commercial channels between the two segments. Collaboration opportunities exist in software expertise, AI innovation, and cost-cutting projects. The company maintains strategic flexibility to operate the segments independently if needed.

Q:What will it take to return the IP segment to organic revenue growth, and what is the realistic time frame?

A:The IP segment is positioned strongly with significant assets and customer base. The company is focusing on innovation, execution, and recurring revenue. New product launches like Derwent Patent Monitor and RiskMark are expected to drive growth. Market recovery in global IP and increased patent filings due to AI are also positive factors. The turnaround will take time but is progressing.

Q:What are the capital allocation priorities, and why focus on deleveraging over buybacks?

A:The company prioritizes deleveraging over buybacks due to the current market environment, despite attractive free cash flow returns. The capital structure is patient, with no maturities for the next few years. The focus on debt repayment is seen as the best way to create value in the near term.

Q:Can you speak about price realization and its impact on ACV and recurring revenue growth?

A:Price realization has been consistent, with growth driven by volume improvements such as higher renewal rates and new subscription sales. The company expects volume growth to continue driving improvements, supported by investments in products and fewer cancellations.

Q:Review of Unclear Management Responses

A:Management avoided providing specific numerical details about the percentage of revenue based on seat licenses in the monetization model. Additionally, while discussing the IP segment's turnaround, the timeline for achieving organic revenue growth was not clearly defined.

You have reached the limit. Sign up to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

CLVT Transcript

Clarivate Plc (CLVT) Q4 2025 Earnings Call Transcript

Positive2-24

Clarivate Plc (CLVT) Presents at Global Technology, Internet, Media & Telecommunications Conference 2025 Transcript

Neutral11-19

Clarivate Plc (CLVT) Q3 2025 Earnings Call Transcript

Unknown10-29

The earnings call presents a mixed outlook. Financial performance showed improvements in ACV and renewal rates, but revenue remained flat, and a net loss was reported. The Q&A highlighted innovation in AI and potential growth in IP, but management's unclear responses on long-term potential and AI's competitive edge raise concerns. Despite raised guidance, the flat revenue and net loss, coupled with market uncertainties, suggest a neutral sentiment. Given the mid-sized market cap, the stock is likely to see minor fluctuations, leading to a neutral prediction of -2% to 2%.

Clarivate Plc (CLVT) Presents At Goldman Sachs Communacopia + Technology Conference 2025 Transcript

Neutral9-11

CLVT Report

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.